The Global Creatinine Test Market is expected to reach USD 2,356.7 Million by 2028, growing at a Compound Annual Growth Rate (CAGR) of 16.1% from 2022 to 2028. The increased prevalence of kidney disorders and chronic conditions leading to kidney diseases along with increasing adoption of point-of-care (POC) diagnostics is anticipated to augment the growth of the market during the forecast period.
- The urine tests segment held a significant share in 2021. This is attributable to the increasing demand for rapid and easy-to-use urine tests across the globe. Furthermore, the growing diagnostics segment is also expected to support the segmental growth of the market.
- The hospital's segment is expected to grow at a considerable Compound Annual Growth Rate (CAGR) during the forecast period. This is owing to the increasing hospital visits due to the rising awareness about CKD and its treatment.
- Asia Pacific is expected to grow at the fastest Compound Annual Growth Rate (CAGR) during the forecast period. This is attributable to the increase in investments by leading market players in emerging economies like India, and China along with the increasing target population in the region. Furthermore, the rapidly developing healthcare facilities are also anticipated to support the regional growth of the market.
Some of key players in Global Creatinine Test Market include - BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.)..
The increasing incidence of kidney disorders across the globe is expected to fuel the growth of the Creatinine Test Market in the years to come. According to National Kidney Foundation, around 37 million people in the U.S. which consists of 15% of the adult population i.e., more than 1 in 7 are affected with kidney disorders. It further estimated that approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure are prone to kidney disease. Thus, kidney disorders are considered to be the leading cause of death globally. This is expected to increase the demand for creatinine tests in the years to come. However, the unfavorable healthcare reforms and lack of predictive value obtained by creatinine tests are expected to hamper the growth of the market in the years to come. Moreover, Integrated and automated systems for overall urine analysis along with an increase in investments are further expected to augment the growth of the market within the forecast period.
North America held the largest shares in 2021. This is attributable to the high awareness levels about CKD in the region. Furthermore, the favorable reimbursement policies & government initiatives in countries like the U.S. is also expected to fuel the regional growth of the market. Additionally, well-established healthcare infrastructure and easy availability of technologically advanced products is also supporting the growth of the Creatinine Test Market in the region.